Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Convertible Debt (2021 - 2022)

Historic Convertible Debt for Ascendis Pharma A (ASND) over the last 2 years, with Q4 2022 value amounting to $407.3 million.

  • Ascendis Pharma A's Convertible Debt rose 11658.18% to $407.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was $407.3 million, marking a year-over-year increase of 11658.18%. This contributed to the annual value of $407.3 million for FY2022, which is 11658.18% up from last year.
  • Ascendis Pharma A's Convertible Debt amounted to $407.3 million in Q4 2022, which was up 11658.18% from $188.0 million recorded in Q4 2021.
  • Ascendis Pharma A's Convertible Debt's 5-year high stood at $407.3 million during Q4 2022, with a 5-year trough of $188.0 million in Q4 2021.